{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T23:16:30Z","timestamp":1777072590235,"version":"3.51.4"},"reference-count":106,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003042","name":"Else Kr\u00f6ner-Fresenius-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ecl.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T23:02:51Z","timestamp":1761087771000},"page":"609-626","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Medical Therapies of Cushing\u2019s Disease\u2013Part 1"],"prefix":"10.1016","volume":"54","author":[{"given":"Yair","family":"Schwarz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reut","family":"Halperin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shruti N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard A.","family":"Feelders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9996","key":"10.1016\/j.ecl.2025.08.002_bib1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","article-title":"Cushing\u2019s syndrome","volume":"386","author":"Lacroix","year":"2015","journal-title":"Lancet (London, England)"},{"issue":"12","key":"10.1016\/j.ecl.2025.08.002_bib2","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","article-title":"Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update","volume":"9","author":"Fleseriu","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib3","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40618-022-01754-1","article-title":"Global Cushing\u2019s disease epidemiology: a systematic review and meta-analysis of observational studies","volume":"45","author":"Giuffrida","year":"2022","journal-title":"J Endocrinol Investig"},{"issue":"SUPPL. 1","key":"10.1016\/j.ecl.2025.08.002_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000314297","article-title":"Epidemiology of Cushing\u2019s syndrome","volume":"92","author":"Steffensen","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib5","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cen.13600","article-title":"Worse Health-Related Quality of Life at long-term follow-up in patients with Cushing\u2019s disease than patients with cortisol producing adenoma. Data from the ERCUSYN","volume":"88","author":"Valassi","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2025.08.002_bib6","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1210\/jc.2015-1818","article-title":"Treatment of cushing\u2019s syndrome: an endocrine society clinical practice guideline","volume":"100","author":"Nieman","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2025.08.002_bib7","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s41574-023-00868-7","article-title":"An individualized approach to the management of Cushing disease","volume":"19","author":"Fleseriu","year":"2023","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s11102-024-01485-x","article-title":"Medical management pathways for Cushing\u2019s disease in pituitary tumors centers of excellence (PTCOEs)","volume":"28","author":"Giustina","year":"2025","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib9","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","article-title":"Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis","volume":"21","author":"Broersen","year":"2018","journal-title":"Pituitary"},{"key":"10.1016\/j.ecl.2025.08.002_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1060884","article-title":"Individualized medical treatment options in Cushing disease","volume":"13","author":"Gilis-Januszewska","year":"2022","journal-title":"Front Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.002_bib11","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1210\/clinem\/dgad098","article-title":"Aggressive pituitary tumors and pituitary carcinomas: from pathology to treatment","volume":"108","author":"Burman","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib12","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1210\/clinem\/dgac588","article-title":"Treatment of Cushing disease with pituitary-targeting seliciclib","volume":"108","author":"Liu","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"January","key":"10.1016\/j.ecl.2025.08.002_bib13","first-page":"1","article-title":"Resistance to dopamine agonists in pituitary tumors: molecular mechanisms","volume":"12","author":"Pivonello","year":"2022","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11154-008-9082-4","article-title":"Somatostatin and dopamine receptors as targets for medical treatment of Cushing\u2019s Syndrome","volume":"10","author":"De Bruin","year":"2009","journal-title":"Rev Endocr Metab Disord"},{"issue":"12","key":"10.1016\/j.ecl.2025.08.002_bib15","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40618-018-0936-7","article-title":"Effect of cabergoline monotherapy in Cushing\u2019s disease: an individual participant data meta-analysis","volume":"41","author":"Palui","year":"2018","journal-title":"J Endocrinol Investig"},{"issue":"12","key":"10.1016\/j.ecl.2025.08.002_bib16","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1007\/s40618-018-0936-7","article-title":"Effect of cabergoline monotherapy in Cushing\u2019 disease: an individual participant data meta-analysis","volume":"41","author":"Palui","year":"2018","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1210\/jc.2008-1533","article-title":"The medical treatment of Cushing\u2019s disease: effectiveness of chronic treatment with the dopamine agonist Cabergoline in patients unsuccessfully treated by surgery","volume":"94","author":"Pivonello","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib18","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1530\/EJE-10-0382","article-title":"Cabergoline monotherapy in the long-term treatment of Cushing\u2019s disease","volume":"163","author":"Godbout","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.4158\/EP10031.OR","article-title":"Efficacy of cabergoline in uncured (persistent or recurrent) cushing disease after pituitary surgical treatment with or without radiotherapy","volume":"16","author":"Lila","year":"2010","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s11102-009-0209-8","article-title":"Effectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing\u2019s disease","volume":"13","author":"Vilar","year":"2010","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib21","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-013-0475-3","article-title":"Combination therapy for Cushing\u2019s disease: effectiveness of two schedules of treatment: should we start with cabergoline or ketoconazole?","volume":"17","author":"Barbot","year":"2014","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1530\/EJE-15-0807","article-title":"Limited value of cabergoline in Cushing\u2019s disease: a prospective study of a 6-week treatment in 20 patients","volume":"174","author":"Burman","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1530\/EJE-16-0662","article-title":"Cabergoline for Cushing\u2019s disease: a large retrospective multicenter study","volume":"176","author":"Ferriere","year":"2017","journal-title":"Eur J Endocrinol"},{"issue":"October","key":"10.1016\/j.ecl.2025.08.002_bib24","first-page":"1","article-title":"Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing\u2019s disease","volume":"14","author":"Feelders","year":"2023","journal-title":"Front Endocrinol"},{"issue":"19","key":"10.1016\/j.ecl.2025.08.002_bib25","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1056\/NEJMc1000094","article-title":"Pasireotide alone or with Cabergoline and ketoconazole in Cushing\u2019s disease","volume":"362","author":"Feelders","year":"2010","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib26","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s11102-022-01244-w","article-title":"Cushing\u2019s disease: role of preoperative and primary medical therapy","volume":"25","author":"Castinetti","year":"2022","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib27","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-17-0997","article-title":"Preoperative medical treatment in Cushing\u2019s syndrome: frequency of use and its impact on postoperative assessment: data from ERCUSYN","volume":"178","author":"Valassi","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib28","doi-asserted-by":"crossref","first-page":"235","DOI":"10.23736\/S2724-6507.21.03622-8","article-title":"The effects of cabergoline in the presurgical and recurrence periods of Cushing\u2019s disease patients","volume":"49","author":"Pereira","year":"2024","journal-title":"Minerva Endocrinol"},{"issue":"MAR","key":"10.1016\/j.ecl.2025.08.002_bib29","first-page":"1","article-title":"Novel somatostatin receptor ligands therapies for acromegaly","volume":"9","author":"Paragliola","year":"2018","journal-title":"Front Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.08.002_bib30","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1159\/000314296","article-title":"Role of somatostatin receptors in normal and tumoral pituitary corticotropic cells","volume":"92","author":"Hofland","year":"2010","journal-title":"Neuroendocrinology"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.002_bib31","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf089","article-title":"A prospective trial with ketoconazole induction therapy and octreotide maintenance treatment for Cushing\u2019s disease","volume":"9","author":"Paes","year":"2025","journal-title":"J Endocr Soc"},{"issue":"12","key":"10.1016\/j.ecl.2025.08.002_bib32","doi-asserted-by":"crossref","first-page":"E1880","DOI":"10.1210\/jc.2013-1987","article-title":"Preoperative normalization of cortisol levels in Cushing\u2019s disease after medical treatment: consequences for somatostatin and dopamine receptor subtype expression and in vitro response to somatostatin analogs and dopamine agonists","volume":"98","author":"van der Pas","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ecl.2025.08.002_bib33","article-title":"Management of Nelson\u2019s syndrome","volume":"58","author":"Fountas","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"10","key":"10.1016\/j.ecl.2025.08.002_bib34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1105743","article-title":"A 12-month phase 3 study of pasireotide in Cushing\u2019s disease","volume":"366","author":"Colao","year":"2012","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib35","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s12020-017-1316-3","article-title":"Long-term treatment of Cushing\u2019s disease with pasireotide: 5-year results from an open-label extension study of a Phase III trial","volume":"57","author":"Petersenn","year":"2017","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib36","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cen.12431","article-title":"Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing\u2019s disease: results from a Phase III study","volume":"81","author":"Pivonello","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib37","doi-asserted-by":"crossref","first-page":"467","DOI":"10.55730\/1300-0144.5335","article-title":"Pasireotide treatment in Cushing\u2019s disease: a single tertiary center\u2019s experience","volume":"52","author":"\u015eahin","year":"2022","journal-title":"Turkish J Med Sci."},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib38","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s12020-018-1818-7","article-title":"The medical treatment with pasireotide in Cushing\u2019s disease: an Italian multicentre experience based on \u201creal-world evidence\u201d","volume":"64","author":"Pivonello","year":"2019","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib39","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/cen.14081","article-title":"Long-term efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a Phase III extension study","volume":"91","author":"Fleseriu","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib40","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1007\/s12020-025-04202-1","article-title":"Efficacy and safety of pasireotide in patients with Cushing\u2019s disease: a monocentric experience","volume":"88","author":"Alessi","year":"2025","journal-title":"Endocrine"},{"issue":"8","key":"10.1016\/j.ecl.2025.08.002_bib41","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.3390\/jcm14082794","article-title":"Real-world experience with pasireotide-LAR in Cushing\u2019s disease: single-center 12-month observational study","volume":"14","author":"Dzialach","year":"2025","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib42","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2213-8587(17)30326-1","article-title":"Efficacy and safety of once-monthly pasireotide in Cushing\u2019s disease: a 12 month clinical trial","volume":"6","author":"Lacroix","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib43","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s11102-019-01021-2","article-title":"Pasireotide treatment significantly reduces tumor volume in patients with Cushing\u2019s disease: results from a Phase 3 study","volume":"23","author":"Lacroix","year":"2020","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib44","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s11102-021-01161-4","article-title":"Managing pasireotide-associated hyperglycemia: a randomized, open-label, Phase IV study","volume":"24","author":"Samson","year":"2021","journal-title":"Pituitary"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib45","doi-asserted-by":"crossref","first-page":"R45","DOI":"10.1093\/ejendo\/lvaf100","article-title":"Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas","volume":"192","author":"Raverot","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib46","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/j.1365-2265.2012.04381.x","article-title":"Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment","volume":"76","author":"Raverot","year":"2012","journal-title":"Clin Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib47","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1530\/EJE-22-0440","article-title":"Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients","volume":"187","author":"Burman","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib48","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s11102-016-0745-y","article-title":"How effective is temozolomide for treating pituitary tumours and when should it be used?","volume":"20","author":"Halevy","year":"2017","journal-title":"Pituitary"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/jama.2023.11305","article-title":"Cushing syndrome: a review","volume":"330","author":"Reincke","year":"2023","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.ecl.2025.08.002_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.arcmed.2023.102908","article-title":"Pharmacological treatment of cushing\u2019s syndrome","volume":"54","author":"Castinetti","year":"2023","journal-title":"Arch Med Res"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib51","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41572-024-00588-w","article-title":"Cushing syndrome","volume":"11","author":"Nieman","year":"2025","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2021.101490","article-title":"Updates in adrenal steroidogenesis inhibitors for Cushing\u2019s syndrome - a practical guide","volume":"35","author":"Varlamov","year":"2021","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib53","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/17446651.2021.1945440","article-title":"Levoketoconazole: a novel treatment for endogenous Cushing\u2019s syndrome","volume":"16","author":"Fleseriu","year":"2021","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib54","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/14656566.2023.2192349","article-title":"An evaluation of pharmacological options for Cushing\u2019s disease: what are the state-of-the-art options?","volume":"24","author":"Martino","year":"2023","journal-title":"Expert Opin Pharmacother"},{"issue":"12","key":"10.1016\/j.ecl.2025.08.002_bib55","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1055\/a-2317-0801","article-title":"Medical therapy of endogenous cushing\u2019s syndrome with steroidogenesis inhibitors: treatment rationale, available drugs, and therapeutic effects","volume":"132","author":"Detomas","year":"2024","journal-title":"Exp Clin Endocrinol diabetes"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib56","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","article-title":"Ketoconazole in Cushing\u2019s disease: is it worth a try?","volume":"99","author":"Castinetti","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.08.002_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.1017331","article-title":"Evaluation of ketoconazole as a treatment for Cushing\u2019s disease in a retrospective cohort","volume":"13","author":"Viecceli","year":"2022","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.002_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1145775","article-title":"Ketoconazole as second-line treatment for Cushing\u2019s disease after transsphenoidal surgery: systematic review and meta-analysis","volume":"14","author":"Viecceli","year":"2023","journal-title":"Front Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib59","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1007\/s11102-022-01262-8","article-title":"Cushing\u2019s disease: adrenal steroidogenesis inhibitors","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"issue":"11","key":"10.1016\/j.ecl.2025.08.002_bib60","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/S2213-8587(19)30313-4","article-title":"Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing\u2019s syndrome (SONICS): a phase 3, multicentre, open-label, single-arm trial","volume":"7","author":"Fleseriu","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib61","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1530\/EJE-22-0506","article-title":"Levoketoconazole treatment in endogenous Cushing\u2019s syndrome: extended evaluation of clinical, biochemical, and radiologic outcomes","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib62","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s11102-022-01263-7","article-title":"Levoketoconazole in the treatment of patients with endogenous Cushing\u2019s syndrome: a double-blind, placebo-controlled, randomized withdrawal study (LOGICS)","volume":"25","author":"Pivonello","year":"2022","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib63","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","article-title":"LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study","volume":"99","author":"Bertagna","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.08.002_bib64","article-title":"Metyrapone treatment in endogenous cushing\u2019s syndrome: results at week 12 from PROMPT, a prospective international multicenter, open-label, phase III\/IV study","volume":"5","author":"Nieman","year":"2021","journal-title":"J Endocr Soc"},{"issue":"11","key":"10.1016\/j.ecl.2025.08.002_bib65","doi-asserted-by":"crossref","first-page":"4146","DOI":"10.1210\/jc.2015-2616","article-title":"Effectiveness of metyrapone in treating cushing\u2019s syndrome: a retrospective multicenter study in 195 patients","volume":"100","author":"Daniel","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib66","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1007\/s12020-018-1675-4","article-title":"Metyrapone treatment in Cushing\u2019s syndrome: a real-life study","volume":"62","author":"Ceccato","year":"2018","journal-title":"Endocrine"},{"key":"10.1016\/j.ecl.2025.08.002_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.903545","article-title":"Metyrapone versus osilodrostat in the short-term therapy of endogenous Cushing\u2019s syndrome: results from a single center cohort study","volume":"13","author":"Detomas","year":"2022","journal-title":"Front Endocrinol"},{"issue":"Pt 5","key":"10.1016\/j.ecl.2025.08.002_bib68","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1258\/acb.2011.011014","article-title":"Comparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11\u03b2-hydroxylase inhibitor metyrapone","volume":"48","author":"Monaghan","year":"2011","journal-title":"Ann Clin Biochem"},{"issue":"8","key":"10.1016\/j.ecl.2025.08.002_bib69","first-page":"3437","article-title":"Osilodrostat is a potential novel steroidogenesis inhibitor for the treatment of Cushing syndrome: an in vitro study","volume":"104","author":"Creemers","year":"2019","journal-title":"J Endocrinol diabetes Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib70","doi-asserted-by":"crossref","first-page":"43","DOI":"10.17925\/EE.2024.20.1.8","article-title":"Osilodrostat: a novel potent inhibitor of 11-beta-hydroxylase for the treatment of Cushing\u2019s syndrome","volume":"20","author":"Pivonello","year":"2024","journal-title":"TouchREVIEWS Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.002_bib71","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf206","article-title":"Chronotherapy with once-daily osilodrostat improves cortisol rhythm, quality of life, and sleep in Cushing\u2019s syndrome","author":"Ferrari","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1007\/s11102-015-0692-z","article-title":"Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease","volume":"19","author":"Fleseriu","year":"2016","journal-title":"Pituitary"},{"issue":"9","key":"10.1016\/j.ecl.2025.08.002_bib73","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/S2213-8587(20)30240-0","article-title":"Efficacy and safety of osilodrostat in patients with Cushing\u2019s disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase","volume":"8","author":"Pivonello","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib74","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1530\/EJE-22-0317","article-title":"Long-term outcomes of osilodrostat in Cushing\u2019s disease: LINC 3 study extension","volume":"187","author":"Fleseriu","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2025.08.002_bib75","doi-asserted-by":"crossref","first-page":"e2882","DOI":"10.1210\/clinem\/dgac178","article-title":"Randomized trial of osilodrostat for the treatment of Cushing disease","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib76","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1007\/s11102-024-01471-3","article-title":"Osilodrostat improves blood pressure and glycemic control in patients with Cushing\u2019s disease: a pooled analysis of LINC 3 and LINC 4 studies","volume":"28","author":"Fleseriu","year":"2025","journal-title":"Pituitary"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib77","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1210\/clinem\/dgaa778","article-title":"Adrenally directed medical therapies for cushing syndrome","volume":"106","author":"Tritos","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib78","doi-asserted-by":"crossref","DOI":"10.1210\/jcemcr\/luae088","article-title":"Prolonged adrenal insufficiency after osilodrostat exposure with eventual recovery of adrenal function","volume":"2","author":"Tejani","year":"2024","journal-title":"JCEM case reports"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib79","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/0039-128X(93)90054-Q","article-title":"Direct inhibitory effect of etomidate on corticosteroid secretion in human pathologic adrenocortical cells","volume":"58","author":"Varga","year":"1993","journal-title":"Steroids"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib80","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1530\/EJE-12-0274","article-title":"Etomidate in the management of hypercortisolaemia in Cushing\u2019s syndrome: a review","volume":"167","author":"Preda","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib81","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvaf039","article-title":"Etomidate in severe cushing syndrome: a systematic review","volume":"9","author":"Muthukuda","year":"2025","journal-title":"J Endocr Soc"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib82","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1210\/jcem-70-5-1426","article-title":"Infusion of low dose etomidate: correction of hypercortisolemia in patients with Cushing\u2019s syndrome and dose-response relationship in normal subjects","volume":"70","author":"Schulte","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1210\/js.2018-00269","article-title":"Continuous etomidate infusion for the management of severe cushing syndrome: validation of a standard protocol","volume":"3","author":"Carroll","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2025.08.002_bib84","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211058583","article-title":"Pharmacological management of severe Cushing\u2019s syndrome: the role of etomidate","volume":"13","author":"Pence","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib85","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0272-6386(97)90577-1","article-title":"Propylene glycol-induced proximal renal tubular cell injury","volume":"30","author":"Yorgin","year":"1997","journal-title":"Am J kidney Dis Off J Natl Kidney Found"},{"issue":"6","key":"10.1016\/j.ecl.2025.08.002_bib86","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","article-title":"Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome","volume":"97","author":"Fleseriu","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2025.08.002_bib87","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","article-title":"Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone","volume":"99","author":"Fleseriu","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2025.08.002_bib88","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.662865","article-title":"Relacorilant, a selective glucocorticoid receptor modulator, induces clinical improvements in patients with Cushing syndrome: results from a prospective, open-label phase 2 study","volume":"12","author":"Pivonello","year":"2021","journal-title":"Front Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib89","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1111\/cen.12332","article-title":"Global clinical response in Cushing\u2019s syndrome patients treated with mifepristone","volume":"80","author":"Katznelson","year":"2014","journal-title":"Clin Endocrinol"},{"issue":"10","key":"10.1016\/j.ecl.2025.08.002_bib90","first-page":"1087","article-title":"Association between mifepristone dose, efficacy, and tolerability in patients with cushing syndrome","volume":"21","author":"Yuen","year":"2015","journal-title":"Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.002_bib91","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12902-015-0059-5","article-title":"Sustained weight loss in patients treated with mifepristone for Cushing\u2019s syndrome: a follow-up analysis of the SEISMIC study and long-term extension","volume":"15","author":"Fein","year":"2015","journal-title":"BMC Endocr Disord"},{"issue":"1","key":"10.1016\/j.ecl.2025.08.002_bib92","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40842-020-00105-4","article-title":"Clinical management of patients with Cushing syndrome treated with mifepristone: consensus recommendations","volume":"6","author":"Brown","year":"2020","journal-title":"Clin diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2025.08.002_bib93","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/phar.1202","article-title":"Mifepristone for management of Cushing\u2019s syndrome","volume":"33","author":"Morgan","year":"2013","journal-title":"Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib94","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11102-022-01227-x","article-title":"Glucocorticoid receptor blockers","volume":"25","author":"Molitch","year":"2022","journal-title":"Pituitary"},{"issue":"4","key":"10.1016\/j.ecl.2025.08.002_bib95","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S2213-8587(18)30155-4","article-title":"Advances in the medical treatment of Cushing\u2019s syndrome","volume":"7","author":"Feelders","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2025.08.002_bib96","article-title":"Peripheral glucocorticoid receptor antagonism by relacorilant with modest HPA axis disinhibition","volume":"256","author":"Viho","year":"2023","journal-title":"J Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.08.002_bib97","article-title":"PMON165 favorable liver safety profile of the selective glucocorticoid receptor modulator relacorilant in healthy and hepatically impaired adults and in patients with cushing syndrome","volume":"6","author":"Moraitis","year":"2022","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2025.08.002_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110312","article-title":"The glucocorticoid receptor modulator relacorilant reverses the immunosuppressive effects of cortisol","volume":"120","author":"Greenstein","year":"2023","journal-title":"Int Immunopharmacol"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2025.08.002_bib99","article-title":"SUN-451 a randomized-withdrawal, placebo-controlled, phase 3 study to assess the efficacy and safety of selective glucocorticoid receptor antagonist, relacorilant, in patients with cushing syndrome (GRACE study)","volume":"3","author":"Auchus","year":"2019","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.ecl.2025.08.002_bib100","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.110.P69","article-title":"Medical treatment of hypercortisolism with relacorilant: final results of the phase 3 GRACE study","author":"Pivonello","year":"2025","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ecl.2025.08.002_bib101","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/j.eprac.2024.09.061","article-title":"Abstract #1885059 open-label extension study evaluating the safety and efficacy of long-term use of relacorilant in patients with endogenous hypercortisolism (cushing syndrome): results from the first interim analysis","volume":"30","author":"Schlafly","year":"2024","journal-title":"Endocr Pract"},{"key":"10.1016\/j.ecl.2025.08.002_bib102","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.110.P3","article-title":"Relacorilant improved blood pressure and maintained other cardiometabolic improvements in long-term study in patients with endogenous hypercortisolism (Cushing syndrome)","author":"Badiu","year":"2025","journal-title":"Endocr Abstr"},{"key":"10.1016\/j.ecl.2025.08.002_bib103","doi-asserted-by":"crossref","DOI":"10.1530\/endoabs.90.EP801","article-title":"An open-label extension study to evaluate the safety of long-term Use of relacorilant in patients with endogenous cushing syndrome","author":"Badiu","year":"2023","journal-title":"Endocr Abstr"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib104","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/cen.13818","article-title":"Mifepristone in the treatment of the ectopic adrenocorticotropic hormone syndrome","volume":"89","author":"Wannachalee","year":"2018","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.ecl.2025.08.002_bib105","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1530\/EJE-07-0458","article-title":"Mifepristone (RU 486) in Cushing\u2019s syndrome","volume":"157","author":"Johanssen","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.ecl.2025.08.002_bib106","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1530\/EJE-09-0098","article-title":"Merits and pitfalls of mifepristone in Cushing\u2019s syndrome","volume":"160","author":"Castinetti","year":"2009","journal-title":"Eur J Endocrinol"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000799?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852925000799?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T03:34:41Z","timestamp":1772940881000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852925000799"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":106,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S0889852925000799"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2025.08.002","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical Therapies of Cushing\u2019s Disease\u2013Part 1","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}